Change log

Change log

Corrections and updates to the Acheron CAA questions and chapters, newest first. Each entry gives the date, where the change applies, the kind of change and the source it was checked against. Entries describe a change in plain words and do not reprint old or new question text.

Content outline The course follows the NCCAA Content Outline (Rev. 2021), as printed in the NCCAA Certification Examination Handbook (Rev. August 1, 2026): six content areas and 39 subsections.

593 entries logged from October 15, 2026 to November 14, 2026. When an answer key changes, earlier answers to that question are rescored, so dashboards and statistics stay accurate. RSS feed of all entries

Showing 151 to 175 of 593 entries.

October 15, 2026 25 entries on this page

  1. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 owner request: bold "2025 change" note (older references and many protocols used 3 mg; AHA 2025 says 1 mg may be adequate). Older 3 mg sourced to SESLHD SESLHDMG/105 (2024) and McIntosh-Yellin, JACC 1993.

  2. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 owner request: bold "2025 change" note (older references and many protocols used 3 mg; AHA 2025 says 1 mg may be adequate). Older 3 mg sourced to SESLHD SESLHDMG/105 (2024) and McIntosh-Yellin, JACC 1993.

  3. Fact corrected 5.E Cardiovascular Drugs

    Chapter 5.E, Cardiovascular Drugs: corrected or clarified a statement of fact.

    Source: Acheron Errata 8 review minors: unsourced 3 mg clause dropped; 5.E sentence no longer ties denervation to central lines; hyphen ranges in the edited rows written with "to".

  4. Fact corrected 5.E Cardiovascular Drugs

    Chapter 5.E, Cardiovascular Drugs: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 review minors: unsourced 3 mg clause dropped; 5.E sentence no longer ties denervation to central lines; hyphen ranges in the edited rows written with "to".

  5. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected or clarified a statement of fact.

    Source: Acheron Errata 8 review minors: unsourced 3 mg clause dropped; 5.E sentence no longer ties denervation to central lines; hyphen ranges in the edited rows written with "to".

  6. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 review minors: unsourced 3 mg clause dropped; 5.E sentence no longer ties denervation to central lines; hyphen ranges in the edited rows written with "to".

  7. Fact corrected 5.E Cardiovascular Drugs

    Chapter 5.E, Cardiovascular Drugs: corrected or clarified a statement of fact.

    Source: Acheron Errata 8: wording matched to 2.A.

  8. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected or clarified a statement of fact.

    Source: Acheron Errata 8: 2.A adenosine sentence tightened to keep the chapter inside its length band.

  9. Fact corrected 5.E Cardiovascular Drugs

    Chapter 5.E, Cardiovascular Drugs: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 (October 14, 2026): reduced first adenosine dose through a central line or after heart transplant now taught per AHA 2025 Part 9 section 17 supportive text (1 mg may be adequate); dipyridamole and carbamazepine per the US label, no number.

  10. Fact corrected 5.E Cardiovascular Drugs

    Chapter 5.E, Cardiovascular Drugs: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 (October 14, 2026): reduced first adenosine dose through a central line or after heart transplant now taught per AHA 2025 Part 9 section 17 supportive text (1 mg may be adequate); dipyridamole and carbamazepine per the US label, no number.

  11. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 (October 14, 2026): reduced first adenosine dose through a central line or after heart transplant now taught per AHA 2025 Part 9 section 17 supportive text (1 mg may be adequate); dipyridamole and carbamazepine per the US label, no number.

  12. Fact corrected 2.A Cardiovascular

    Chapter 2.A, Cardiovascular: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron Errata 8 (October 14, 2026): reduced first adenosine dose through a central line or after heart transplant now taught per AHA 2025 Part 9 section 17 supportive text (1 mg may be adequate); dipyridamole and carbamazepine per the US label, no number.

  13. Chapter 1.A, Preoperative Evaluation: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: anion gap normal range harmonized with 2.E.2).

  14. Chapter 1.A, Preoperative Evaluation: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: anion gap normal range harmonized with 2.E.2).

  15. Fact corrected 2.F Hepatic and GI

    Chapter 2.F, Hepatic and GI: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: name 3 WU as the older transplant criterion beside the 2022 ESC/ERS >2 WU threshold; anion gap range harmonized with 2.E.2).

  16. Fact corrected 2.F Hepatic and GI

    Chapter 2.F, Hepatic and GI: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: name 3 WU as the older transplant criterion beside the 2022 ESC/ERS >2 WU threshold; anion gap range harmonized with 2.E.2).

  17. Fact corrected 2.F Hepatic and GI

    Chapter 2.F, Hepatic and GI: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: name 3 WU as the older transplant criterion beside the 2022 ESC/ERS >2 WU threshold; anion gap range harmonized with 2.E.2).

  18. Fact corrected 2.F Hepatic and GI

    Chapter 2.F, Hepatic and GI: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: name 3 WU as the older transplant criterion beside the 2022 ESC/ERS >2 WU threshold; anion gap range harmonized with 2.E.2).

  19. Fact corrected 2.F Hepatic and GI

    Chapter 2.F, Hepatic and GI: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: name 3 WU as the older transplant criterion beside the 2022 ESC/ERS >2 WU threshold; anion gap range harmonized with 2.E.2).

  20. Chapter 5.F, Non-Anesthetic Drugs and Adjuncts: corrected a value in the text (a dose, threshold or other number).

    Source: Acheron editorial review (Mock-link follow-up: redosing interval from the preoperative dose, blood loss above 1,500 mL (ASHP/IDSA/SIS/SHEA 2013); CDC 2017 no doses after closure (JAMA Surg 2017;152:784, PMID 28467526)).

  21. Chapter 5.F, Non-Anesthetic Drugs and Adjuncts: corrected or clarified a statement of fact.

    Source: Acheron editorial review (Mock-link follow-up: redosing interval from the preoperative dose, blood loss above 1,500 mL (ASHP/IDSA/SIS/SHEA 2013); CDC 2017 no doses after closure (JAMA Surg 2017;152:784, PMID 28467526)).

  22. Chapter 5.F, Non-Anesthetic Drugs and Adjuncts: corrected or clarified a statement of fact.

    Source: Acheron editorial review (US English (October 12, 2026)).

  23. Fact corrected 4.K Gastrointestinal

    Chapter 4.K, Gastrointestinal: corrected or clarified a statement of fact.

    Source: Acheron editorial review (US English (October 12, 2026)).

  24. Chapter 4.J, Ambulatory Surgery: reworded a passage for clarity.

    Source: Acheron editorial review (US English (October 12, 2026)).

  25. Chapter 4.G, Trauma and Burns: reworded a passage for clarity.

    Source: Acheron editorial review (US English (October 12, 2026)).

What the types mean
Key changed
The correct answer of a question changed. Earlier answers to it are rescored.
Fact corrected
A value, dose, threshold or statement in a question or chapter was wrong or out of date and has been fixed.
Reference updated
The source cited for a question or chapter was replaced with a current one.
Item retired
A question was taken out of use, usually because it could not be made accurate or fair.
New items
Questions were added.
Wording
Text was made clearer without changing its meaning or its answer.
Feature
A change to how the Study Suite works.

Students with an account can use Report a problem on any question or course page. A report that leads to a correction is logged here.